Cargando…
Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease
Alzheimer’s disease is a neurodegenerative disorder that causes age-dependent neurological and cognitive declines. The treatments for Alzheimer’s disease pose a significant challenge, because the mechanisms of disease are not being fully understood. Malfunction of the blood–brain barrier is increasi...
Autores principales: | , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762951/ https://www.ncbi.nlm.nih.gov/pubmed/35788280 http://dx.doi.org/10.1093/brain/awac236 |
_version_ | 1784852959434113024 |
---|---|
author | Wang, Qi Huang, Xiaomin Su, Yixun Yin, Guowei Wang, Shouyu Yu, Bin Li, Hui Qi, Junhua Chen, Hui Zeng, Wen Zhang, Kai Verkhratsky, Alexei Niu, Jianqin Yi, Chenju |
author_facet | Wang, Qi Huang, Xiaomin Su, Yixun Yin, Guowei Wang, Shouyu Yu, Bin Li, Hui Qi, Junhua Chen, Hui Zeng, Wen Zhang, Kai Verkhratsky, Alexei Niu, Jianqin Yi, Chenju |
author_sort | Wang, Qi |
collection | PubMed |
description | Alzheimer’s disease is a neurodegenerative disorder that causes age-dependent neurological and cognitive declines. The treatments for Alzheimer’s disease pose a significant challenge, because the mechanisms of disease are not being fully understood. Malfunction of the blood–brain barrier is increasingly recognized as a major contributor to the pathophysiology of Alzheimer’s disease, especially at the early stages of the disease. However, the underlying mechanisms remain poorly characterized, while few molecules can directly target and improve blood–brain barrier function in the context of Alzheimer’s disease. Here, we showed dysfunctional blood–brain barrier in patients with Alzheimer’s disease reflected by perivascular accumulation of blood-derived fibrinogen in the hippocampus and cortex, accompanied by decreased tight junction proteins Claudin-5 and glucose transporter Glut-1 in the brain endothelial cells. In the APP(swe)/PS1(dE9) (APP/PS1) mouse model of Alzheimer’s disease, blood–brain barrier dysfunction started at 4 months of age and became severe at 9 months of age. In the cerebral microvessels of APP/PS1 mice and amyloid-β-treated brain endothelial cells, we found suppressed Wnt/β-catenin signalling triggered by an increase of GSK3β activation, but not an inhibition of the AKT pathway or switching to the Wnt/planar cell polarity pathway. Furthermore, using our newly developed optogenetic tool for controlled regulation of LRP6 (upstream regulator of the Wnt signalling) to activate Wnt/β-catenin pathway, blood–brain barrier malfunction was restored by preventing amyloid-β-induced brain endothelial cells impairments and promoting the barrier repair. In conclusion, targeting LRP6 in the Wnt/β-catenin pathway in the brain endothelium can alleviate blood–brain barrier malfunction induced by amyloid-β, which may be a potential treatment strategy for Alzheimer’s disease. |
format | Online Article Text |
id | pubmed-9762951 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-97629512022-12-20 Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease Wang, Qi Huang, Xiaomin Su, Yixun Yin, Guowei Wang, Shouyu Yu, Bin Li, Hui Qi, Junhua Chen, Hui Zeng, Wen Zhang, Kai Verkhratsky, Alexei Niu, Jianqin Yi, Chenju Brain Original Article Alzheimer’s disease is a neurodegenerative disorder that causes age-dependent neurological and cognitive declines. The treatments for Alzheimer’s disease pose a significant challenge, because the mechanisms of disease are not being fully understood. Malfunction of the blood–brain barrier is increasingly recognized as a major contributor to the pathophysiology of Alzheimer’s disease, especially at the early stages of the disease. However, the underlying mechanisms remain poorly characterized, while few molecules can directly target and improve blood–brain barrier function in the context of Alzheimer’s disease. Here, we showed dysfunctional blood–brain barrier in patients with Alzheimer’s disease reflected by perivascular accumulation of blood-derived fibrinogen in the hippocampus and cortex, accompanied by decreased tight junction proteins Claudin-5 and glucose transporter Glut-1 in the brain endothelial cells. In the APP(swe)/PS1(dE9) (APP/PS1) mouse model of Alzheimer’s disease, blood–brain barrier dysfunction started at 4 months of age and became severe at 9 months of age. In the cerebral microvessels of APP/PS1 mice and amyloid-β-treated brain endothelial cells, we found suppressed Wnt/β-catenin signalling triggered by an increase of GSK3β activation, but not an inhibition of the AKT pathway or switching to the Wnt/planar cell polarity pathway. Furthermore, using our newly developed optogenetic tool for controlled regulation of LRP6 (upstream regulator of the Wnt signalling) to activate Wnt/β-catenin pathway, blood–brain barrier malfunction was restored by preventing amyloid-β-induced brain endothelial cells impairments and promoting the barrier repair. In conclusion, targeting LRP6 in the Wnt/β-catenin pathway in the brain endothelium can alleviate blood–brain barrier malfunction induced by amyloid-β, which may be a potential treatment strategy for Alzheimer’s disease. Oxford University Press 2022-07-05 /pmc/articles/PMC9762951/ /pubmed/35788280 http://dx.doi.org/10.1093/brain/awac236 Text en © The Author(s) 2022. Published by Oxford University Press on behalf of the Guarantors of Brain. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com |
spellingShingle | Original Article Wang, Qi Huang, Xiaomin Su, Yixun Yin, Guowei Wang, Shouyu Yu, Bin Li, Hui Qi, Junhua Chen, Hui Zeng, Wen Zhang, Kai Verkhratsky, Alexei Niu, Jianqin Yi, Chenju Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title | Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title_full | Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title_fullStr | Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title_full_unstemmed | Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title_short | Activation of Wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in Alzheimer’s disease |
title_sort | activation of wnt/β-catenin pathway mitigates blood–brain barrier dysfunction in alzheimer’s disease |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9762951/ https://www.ncbi.nlm.nih.gov/pubmed/35788280 http://dx.doi.org/10.1093/brain/awac236 |
work_keys_str_mv | AT wangqi activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT huangxiaomin activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT suyixun activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT yinguowei activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT wangshouyu activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT yubin activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT lihui activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT qijunhua activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT chenhui activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT zengwen activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT zhangkai activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT verkhratskyalexei activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT niujianqin activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease AT yichenju activationofwntbcateninpathwaymitigatesbloodbrainbarrierdysfunctioninalzheimersdisease |